New combo therapy aims to improve leukemia outcomes in older adults
NCT ID NCT03586609
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests whether adding venetoclax to a chemotherapy regimen of cladribine, low dose cytarabine, and azacitidine can improve remission rates in adults aged 50 and older with untreated acute myeloid leukemia. The study involves 145 participants and uses a two-stage design to evaluate how well the combination works. The goal is to find a more effective treatment option for patients who may not tolerate standard intensive chemotherapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
venetoclax, cladribine, low dose cytarabine, and azacitidine
What this could lead to
If this works, it could offer a more effective treatment option for older adults with untreated acute myeloid leukemia who cannot tolerate standard intensive chemotherapy.
What could go wrong
This is a Phase 2 trial, so it is still early. The combination may cause serious side effects, and it is not yet known if it improves survival compared to existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact